SIGNATURE WORK
CONFERENCE & EXHIBITION 2022

Breast, cervical, and ovarian cancer are among the most common cancers in women. The three cancer types contribute a significant burden of new cancer cases in women where they make up 24.7%, 6.6%, and 3.2% of all cases in women each year. The TGF-β family of growth factors and its signaling pathway have been widely implicated in the progression of these types of cancers where TGF-β has been shown previously to promote tumor growth and metastasis. Consequently, various inhibitors of TGF-β receptors such as LY364947 have been developed as potential therapeutic options for cancer. However, data on the effects of such TGF-β receptor inhibitors on different cell lines still remains sparse. That said, this project aimed to form a rigorous evaluation of the TGF-β type I receptor LY364947 on limiting the proliferation of breast, cervical, and ovarian cancer cell lines to better inform future approaches to the development of cancer therapeutics.